Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: stockdoc77 who wrote (31106)	6/24/2015 1:32:51 PM
From: gary123	1 Recommendation Recommended By captcobra1 Read Replies (1) \| Respond to of 63283

Doc, I agree with you on 132 backstopping any price collapse in case of negative binary, in fact, I have stated the year's delay might turn out to be a good thing This summer's delay may also prove to be a positive as we are slated to get data in two weeks in Spain. Hopefully we get updated data in all indication before binary. Wall street have ignored 132 so far, because they feel that 132 has to run in a randomized P2. The only way to bypass this is exceptional data, If 132 can achieve a 9 months PFS, in TNBC, it will qualify as a "breakthrough" drug. The last update was from scans in early April, we got 6 mts PFS, however, 56% of patients are still in progression free mode, even if we discount that number by 10%-15% per month we can still hit 9 mts PFS, which will dramatically increase the value of the agent. A price trajectory like Puma Biotech is likely in such a scenario.